相似文献
1
Vaccine design reaches the atomic level.
Sci Transl Med. 2011 Jul 13;3(91):91ps29. doi: 10.1126/scitranslmed.3002807.
2
Rational design of a meningococcal antigen inducing broad protective immunity.
Sci Transl Med. 2011 Jul 13;3(91):91ra62. doi: 10.1126/scitranslmed.3002234.
3
Vaccines, reverse vaccinology, and bacterial pathogenesis.
Cold Spring Harb Perspect Med. 2013 May 1;3(5):a012476. doi: 10.1101/cshperspect.a012476.
4
Novel approaches to Neisseria meningitidis vaccine design.
Pathog Dis. 2017 Apr 1;75(3). doi: 10.1093/femspd/ftx033.
5
The Impact of Nucleotide Sequence Analysis on Meningococcal Vaccine Development and Assessment.
Front Immunol. 2019 Jan 15;9:3151. doi: 10.3389/fimmu.2018.03151. eCollection 2018.
6
Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains.
Infect Immun. 2002 Nov;70(11):6021-31. doi: 10.1128/IAI.70.11.6021-6031.2002.
7
Reverse vaccinology, a genome-based approach to vaccine development.
Vaccine. 2001 Mar 21;19(17-19):2688-91. doi: 10.1016/s0264-410x(00)00554-5.
8
Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease.
Microbiol Mol Biol Rev. 2013 Jun;77(2):234-52. doi: 10.1128/MMBR.00056-12.
9
Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules.
PLoS Pathog. 2012;8(10):e1002981. doi: 10.1371/journal.ppat.1002981. Epub 2012 Oct 25.
10
The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology.
Front Immunol. 2019 Apr 16;10:751. doi: 10.3389/fimmu.2019.00751. eCollection 2019.
引用本文的文献
1
Structure-based vaccines provide protection in a mouse model of ehrlichiosis.
PLoS One. 2011;6(11):e27981. doi: 10.1371/journal.pone.0027981. Epub 2011 Nov 17.
本文引用的文献
1
Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus.
J Mol Biol. 2011 Jun 24;409(5):853-66. doi: 10.1016/j.jmb.2011.04.044. Epub 2011 Apr 27.
2
Structure of the uncomplexed Neisseria meningitidis factor H-binding protein fHbp (rLP2086).
Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 May 1;67(Pt 5):531-5. doi: 10.1107/S1744309111006154. Epub 2011 Apr 20.
3
Elicitation of structure-specific antibodies by epitope scaffolds.
Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):17880-7. doi: 10.1073/pnas.1004728107. Epub 2010 Sep 27.
4
Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope.
Structure. 2010 Sep 8;18(9):1116-26. doi: 10.1016/j.str.2010.06.010.
5
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.
Science. 2010 Aug 13;329(5993):856-61. doi: 10.1126/science.1187659. Epub 2010 Jul 8.
6
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.
Science. 2010 Aug 13;329(5993):811-7. doi: 10.1126/science.1192819. Epub 2010 Jul 8.
7
Complement control protein factor H: the good, the bad, and the inadequate.
Mol Immunol. 2010 Aug;47(13):2187-97. doi: 10.1016/j.molimm.2010.05.007.
8
Review of meningococcal group B vaccines.
Clin Infect Dis. 2010 Mar 1;50 Suppl 2(S2):S54-65. doi: 10.1086/648966.
9
Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection.
Vaccine. 2010 Mar 11;28(12):2416-27. doi: 10.1016/j.vaccine.2009.12.082. Epub 2010 Jan 10.
10
Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region.
J Virol. 2010 Mar;84(6):2955-62. doi: 10.1128/JVI.02257-09. Epub 2009 Dec 30.
Zotero 插件